Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 10/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 10/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800347 | 1.00 | KMT2A (0.50) | KMT2APPARGEPHX2PPARACYP1A2 | |
| SCHEMBL22800417 | 0.82 | FAAH (0.45) | KMT2APPARGEPHX2PPARAMEN1 | |
| SCHEMBL22800416 | 0.82 | FAAH (0.45) | KMT2APPARGEPHX2PPARAMEN1 | |
| SCHEMBL4663230 | 0.79 | CYP1A2 (0.65) | KMT2APPARGEPHX2PPARACYP1A2 | |
| SCHEMBL22800405 | 0.78 | SLC6A2 (0.39) | KMT2APPARGPPARA | |
| SCHEMBL22800406 | 0.78 | SLC6A2 (0.39) | KMT2APPARGPPARA | |
| SCHEMBL22800354 | 0.78 | CYP1A2 (0.38) | KMT2APPARGEPHX2PPARACYP1A2 | |
| SCHEMBL22800353 | 0.78 | CYP1A2 (0.38) | KMT2APPARGEPHX2PPARACYP1A2 | |
| SCHEMBL8446169 | 0.77 | KMT2A (0.47) | KMT2APPARGEPHX2PPARACYP1A2 | |
| SCHEMBL6155501 | 0.77 | KMT2A (0.47) | KMT2APPARGEPHX2PPARACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046652-B2 | Hydroxamic acids comprising pyrazole moiety and uses thereof | HAWAII BIOTECH, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020263995-A1 | HYDROXAMIC ACIDS COMPRISING PYRAZOLE MOIETY AND USES THEREOF | HAWAII BIOTECH, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-20200399223-A1 | HYDROXAMIC ACIDS COMPRISING PYRAZOLE MOIETY AND USES THEREOF | HAWAII BIOTECH, INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046652-B2 | Hydroxamic acids comprising pyrazole moiety and uses thereof | HRH2, HRH3, HCAR3 | KMT2A 4185/4885PPARG 1417/4885EPHX2 745/4885 |
| US-20200399223-A1 | HYDROXAMIC ACIDS COMPRISING PYRAZOLE MOIETY AND USES THEREOF | HRH2, HRH3, HCAR3 | KMT2A 4185/4885PPARG 1417/4885EPHX2 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.